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Summary of findings {#CD011547-sec1-0001}
===================

Summary of findings for the main comparisonArtemisinin‐naphthoquine versus AL for treating uncomplicated *P. falciparum* malaria**Artemisinin‐naphthoquine versus AL for treating uncomplicated *P. falciparum* malariaPatient or population:** Adults and children with uncomplicated *P. falciparum* malaria **Settings:** Malaria endemic settings **Intervention:** Artemisinin‐naphthoquine (ART‐NQ) (one or three‐day course) **Comparison:** Artemether‐lumefantrine (AL) (three‐day course)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskALART‐NQTreatment failure at day 28PCR‐unadjustedRR 1.02** (0.24 to 4.37)487 (3 trials)⊕⊕⊝⊝ **low**^1,2,3,4^**1 per 1001 per 100** (0 to 4)**PCR‐adjustedRR 1.03** (0.15 to 7.07)485 (3 trials)⊕⊕⊝⊝ **low**^1,2,3,4^**0 per 1000 per 100** (0 to 0)**Treatment failure at day 42PCR‐unadjustedRR 0.09**\
(0.00 to 1.59)186\
(1 trial)⊕⊝⊝⊝ **very low**^5,6,7^**5 per 1000 per 100** (0 to 8)**PCR‐adjustedRR 0.33**\
(0.01 to 7.91)186\
(1 trial)⊕⊝⊝⊝ **very low**^5,6,7^**1 per 1000 per 100** (0 to 8)The basis for the **assumed risk** is the mean control group risk across included studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Summary of findings 2Artemisinin‐naphthoquine versus DHA‐P for treating uncomplicated *P. falciparum* malaria**Artemisinin‐naphthoquine versus DHA‐P for treating uncomplicated *P. falciparum* malariaPatient or population:** Adults and children with uncomplicated *P. falciparum* malaria **Settings:** Malaria endemic settings **Intervention:** Artemisinin‐naphthoquine (ART‐NQ) (one‐day course) **Comparison:** Dihydroartemisinin‐piperaquine (DHA‐P) (three‐day course)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskDHA‐PART‐NQTreatment failure at day 28PCR‐unadjusted**Not estimable143 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^**0 per 1000 per 100PCR‐adjusted**Not estimable143 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^**0 per 1000 per 100Treatment failure at day 42PCR‐unadjustedRR 0.91** (0.13 to 6.26)143 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^**3 per 1003 per 100** (0 to 19)**PCR‐adjustedRR 0.19** (0.01 to 3.82)141 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^**3 per 1000 per 100** (0 to 11)The basis for the **assumed risk** is the mean control group risk on the included studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^3]

Background {#CD011547-sec1-0002}
==========

Description of the condition {#CD011547-sec2-0001}
----------------------------

Malaria is a febrile illness caused by infection with the protozoan parasite *Plasmodium*, and transmitted from person to person by the bite of infected mosquitoes. Five *Plasmodium* species are capable of causing malaria in humans, of which *Plasmodium falciparum* is the most common, responsible for over 90% of cases and almost all of the malaria deaths worldwide ([@CD011547-bbs2-0040]).

Uncomplicated malaria is the mild form of the disease, characterised by fever with or without associated headache, tiredness, muscle pains, abdominal pains, rigors, and nausea and vomiting ([@CD011547-bbs2-0037]). If left untreated, uncomplicated malaria can rapidly develop into severe, life threatening forms of the disease, particularly in those without acquired immunity. Effective immunity generally requires repeated infections over five to 10 years, and is reduced during pregnancy. Consequently, in highly endemic settings, as seen in many areas of rural sub‐Saharan Africa, young children and pregnant women are most at risk, while in settings with low or seasonal transmission, all age groups can be equally at risk ([@CD011547-bbs2-0037]).

*P. falciparum* has now developed resistance in many parts of the world to most antimalarial drugs used as monotherapy ([@CD011547-bbs2-0035]; [@CD011547-bbs2-0038]). Consequently, the World Health Organization (WHO) now recommends that *P. falciparum* malaria is always treated with a combination of two drugs that act at different biochemical sites within the parasite ([@CD011547-bbs2-0037]). If a parasite mutation producing drug resistance arises spontaneously during treatment, the parasite should then be killed by the partner drug, reducing or delaying the development of resistance, and increasing the useful lifetime of the individual drugs ([@CD011547-bbs2-0032]; [@CD011547-bbs2-0033]).

Description of the intervention {#CD011547-sec2-0002}
-------------------------------

Five artemisinin‐based combination therapies (ACTs) are recommended for the first‐line treatment of uncomplicated malaria; artemether‐lumefantrine (AL), artesunate plus amodiaquine (AS+AQ), artesunate plus mefloquine (AS+MQ), artesunate plus sulphadoxine‐pyrimethamine (AS+SP), and dihydroartemisinin‐piperaquine (DHA‐P) ([@CD011547-bbs2-0037]). The artemisinin components (artemether, artesunate, and dihydroartemisinin) are highly effective schizonticides, and over three days of treatment rapidly eliminate up to 90% of the blood stage asexual forms of *P. falciparum*. The partner drugs are longer acting and are used to clear any residual infection ([@CD011547-bbs2-0037]). The combinations with very long half‐lives (AS+MQ and DHA‐P), can provide a period of post‐treatment prophylaxis which may last for up to six weeks ([@CD011547-bbs2-0031]).

Artemisinin‐naphthoquine is a new ACT developed by the Academy of Military Medical Sciences Research Institute for Microbial Epidemics in China ([@CD011547-bbs2-0015]). Contrary to the WHO recommendation for three‐days of the artemisinin‐derivative ([@CD011547-bbs2-0037]), this combination is being promoted for use as either a single dose or two dose regimen administered over 24 hours ([@CD011547-bbs2-0023]). The rationale provided for the shortened regimen is to improve compliance with treatment.

Naphthoquine is a tetra‐aminoquinoline that was developed in China in the late 1980s. Whilst it was used as monotherapy within China, it has never been widely used in other countries ([@CD011547-bbs2-0023]). It is reported to be well absorbed orally, with high bioavailability, and is excreted mainly via the kidneys ([@CD011547-bbs2-0015]). Several pharmacokinetic studies are available but with conflicting estimates of the elimination half‐life ([@CD011547-bbs2-0009]). Early reports were of a half‐life of two to three days ([@CD011547-bbs2-0015]), but subsequent published studies found a mean half‐life of 10.6 days in healthy adult Chinese volunteers ([@CD011547-bbs2-0029]), and 22.8 days in children aged five to 12 years with malaria ([@CD011547-bbs2-0005]). For comparison, the elimination half‐lives of lumefantrine and mefloquine in people with uncomplicated malaria are around three days, and 14 days respectively ([@CD011547-bbs2-0020]; [@CD011547-bbs2-0024]; [@CD011547-bbs2-0037]).

Artemisinin is a naturally occurring antimalarial compound which can be extracted from the plant *Artemisia annua*. Since its discovery in the 1970s, product development has concentrated on its semi‐synthetic derivatives (artesunate, artemether, dihydroartemisinin) due to the poor water solubility of artemisinin ([@CD011547-bbs2-0027]; [@CD011547-bbs2-0041]). Once absorbed, these derivatives are rapidly converted to the active metabolite dihydroartemisinin. Parasites resistant to the artemisinin derivatives were first reported in Cambodia in 2007 ([@CD011547-bbs2-0026]), and confirmed in Cambodia in 2008 ([@CD011547-bbs2-0019]), and in Thailand in 2012 ([@CD011547-bbs2-0028]; [@CD011547-bbs2-0039]).

### Assessment of antimalarial drug efficacy {#CD011547-sec3-0001}

The WHO recommends that new antimalarials should have a treatment failure rate of less than 5%, and failure rates with existing first‐line antimalarials higher than 10% should trigger a change in treatment policy ([@CD011547-bbs2-0037]).

The late reappearance of *P. falciparum* parasites in the blood can be due to failure of the drug to completely clear the original parasite infection (a recrudescence) or due to a new infection, which is especially common in areas of high transmission. A molecular genotyping technique called polymerase chain reaction (PCR) can be used in clinical trials to distinguish between recrudescence and new infection, giving a clearer picture of the efficacy of the drug and its post‐treatment prophylactic effect ([@CD011547-bbs2-0018]; [@CD011547-bbs2-0034]; [@CD011547-bbs2-0036]).

The WHO recommends a minimum follow‐up period of 28 days for antimalarial efficacy trials, but longer periods of follow‐up may be required for antimalarials with long elimination half‐lives ([@CD011547-bbs2-0016]; [@CD011547-bbs2-0034]). This is because treatment failure due to true recrudescence of malaria parasites may be delayed until the drug concentration falls below the minimum concentration required to inhibit parasite multiplication, which may be beyond 28 days. The WHO recommends 42 days follow‐up for trials involving lumefantrine and piperaquine and 63 days for trials of mefloquine ([@CD011547-bbs2-0037]).

Why it is important to do this review {#CD011547-sec2-0003}
-------------------------------------

This Cochrane Review aims to systematically evaluate the available studies on the efficacy and safety of the artemisinin‐naphthoquine combination for consideration by global and national policy makers.

Objectives {#CD011547-sec1-0003}
==========

To evaluate the efficacy and safety of the artemisinin‐naphthoquine combination for treating adults and children with uncomplicated *P. falciparum* malaria.

Methods {#CD011547-sec1-0004}
=======

Criteria for considering studies for this review {#CD011547-sec2-0004}
------------------------------------------------

### Types of studies {#CD011547-sec3-0002}

Randomized controlled trials (RCTs). We excluded quasi‐RCTs.

### Types of participants {#CD011547-sec3-0003}

Adults and children (including pregnant women and infants) with symptomatic, microscopically confirmed, uncomplicated *P. falciparum* malaria.

### Types of interventions {#CD011547-sec3-0004}

#### Intervention {#CD011547-sec4-0001}

A course of artemisinin‐naphthoquine given as a single dose, or multiple doses over one, two, or three days.

#### Control {#CD011547-sec4-0002}

A three‐day course of a WHO‐recommended ACT.

*The specific ACTs included are: DHA‐P; AS+MQ; AL (six doses); AS+AQ; and AS+SP.*

### Types of outcome measures {#CD011547-sec3-0005}

#### Primary outcomes {#CD011547-sec4-0003}

Treatment failure at Days 28, 42, and 63; PCR‐adjusted and PCR‐unadjusted.

#### Secondary outcomes {#CD011547-sec4-0004}

Fever clearance.Parasite clearance.Gametocyte carriage at Day 7 or 14 (preference for Day 14 in data analysis).Gametocyte development (negative at baseline, and positive at follow‐up).Change in haemoglobin from baseline (minimum 28 day follow‐up).

##### Adverse events {#CD011547-sec5-0001}

Deaths occurring during follow‐up.Serious adverse events (life threatening, causing admission to hospital, or discontinuation of treatment).Haematological and biochemical adverse effects (for example, neutropenia, liver toxicity).Early vomiting.Other adverse events.

Search methods for identification of studies {#CD011547-sec2-0005}
--------------------------------------------

### Electronic searches {#CD011547-sec3-0006}

We searched the following databases up to 13 January 2015 using the search terms detailed in [Appendix 1](#CD011547-sec2-0015){ref-type="app"}: Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) published in *The Cochrane Library*; MEDLINE; EMBASE; and LILACS.

### Searching other resources {#CD011547-sec3-0007}

We contacted the manufacturer of artemisinin‐naphthoquine in October 2013 requesting further unpublished data.

We also checked the reference lists of all trials identified by the database search.

Data collection and analysis {#CD011547-sec2-0006}
----------------------------

### Selection of studies {#CD011547-sec3-0008}

Rachel Isba (RI) and Babalwa Zani (BZ) independently reviewed the results of the literature search and obtained full‐text copies of all potentially relevant trials. We checked each trial report for evidence of multiple publications from the same data set. RI and BZ then independently assessed each trial for inclusion in this review using an eligibility form based on the inclusion criteria. We resolved any disagreements through discussion or, where necessary, by consultation with DS. If clarification was necessary, we attempted to contact the trial authors for further information.

### Data extraction and management {#CD011547-sec3-0009}

Two review authors (RI and BZ) independently extracted data using a pre‐tested data extraction form. We extracted data on trial characteristics including methods, participants, interventions, and outcomes as well as data on dose and drug ratios of the combinations.

We extracted the number of participants randomized and the number analysed in each treatment group for each outcome. We calculated and report the loss to follow‐up in each group.

For dichotomous outcomes, we recorded the number of participants experiencing the event and the number of participants in each treatment group. For continuous outcomes, we extracted the arithmetic means and standard deviations for each treatment group together with the numbers of participants in each group. If the data were reported using geometric means, we recorded this information and extracted standard deviations on the log scale. If medians were reported we extracted medians and ranges.

#### Primary outcome {#CD011547-sec4-0005}

Our primary analysis drew on the WHO protocol for assessing and monitoring antimalarial drug efficacy ([@CD011547-bbs2-0016]). This protocol has been used to guide most efficacy trials since its publication in 2003, even though it was designed to assess the level of antimalarial resistance in the study area rather than for comparative trials. As a consequence, a high number of randomized participants are excluded from the final efficacy outcome as losses to follow‐up, or voluntary or involuntary withdrawals. For this reason we conducted a sensitivity analysis to restore the integrity of the randomization process and test the robustness of the results to this methodology. (For a summary of the methodology and sensitivity analysis see [Table 5](#CD011547-tbl-0005){ref-type="table"}).Table 1Primary outcome measure (Total failure)**AnalysisParticipantsPCR^b^‐unadjustedPCR‐adjustedNumeratorDenominatorNumeratorDenominator**Primary analysis^a^Exclusions after enrolmentExcluded^c^ExcludedExcludedExcludedMissing or indeterminate PCRIncluded as failuresIncludedExcludedExcludedNew infectionsIncluded as failuresIncludedExcludedExcludedSensitivity analysis 1^d^As \'Primary analysis\' except: missing or indeterminate PCR------Included as failuresIncludedSensitivity analysis 2^e^As \'Sensitivity analysis 1\' except: new infections------Included as successesIncludedSensitivity analysis 3^f^As \'Sensitivity analysis 2\' except: exclusions after enrolmentIncluded as failuresIncludedIncluded as failuresIncludedSensitivity analysis 4^g^As \'Sensitivity analysis 2\' except: exclusions after enrolmentIncluded as successesIncludedIncluded as successesIncluded[^4]

##### PCR‐unadjusted total failure {#CD011547-sec5-0002}

We calculated PCR‐unadjusted total failure (*P. falciparum*) as the sum of early treatment failures and late treatment failures (without PCR adjustment). The denominator excluded participants for whom an outcome was not available (for example, those who were lost to follow‐up, withdrew consent, took other antimalarials, or failed to complete treatment) and those participants who were found not to fulfil the inclusion criteria after randomization.

##### PCR‐adjusted total failure {#CD011547-sec5-0003}

PCR‐adjusted total failure (*P. falciparum*) was calculated as the sum of early treatment failures plus late treatment failures due to PCR‐confirmed recrudescence. We treated participants with indeterminate PCR results, missing PCR results, or PCR‐confirmed new infections as involuntary withdrawals and excluded them from the calculation. The denominator excludes participants for whom an outcome was not available (for example, those who were lost to follow‐up, withdrew consent, took other antimalarials, or failed to complete treatment) and those participants who were found not to fulfil the inclusion criteria after randomization.

These primary outcomes relate solely to failure due to *P. falciparum*. For both PCR‐unadjusted and PCR‐adjusted total failure, participants infected with *P. vivax* during follow‐up were retained in the calculation if they were treated with chloroquine and continued in follow‐up. As long as they did not go on to develop *P. falciparum* parasitaemia they were classified as treatment successes. We excluded from the calculation those participants who were infected with *P. vivax* and were removed from the trial\'s follow‐up at the time of *P. vivax* parasitaemia.

### Assessment of risk of bias in included studies {#CD011547-sec3-0010}

Two review authors (RI and BZ) independently assessed the risk of bias for each trial using The Cochrane Collaboration\'s tool for assessing the \'Risk of bias\' ([@CD011547-bbs2-0022]). We resolved any differences of opinion through discussion with a third review author. We followed the guidance to assess whether adequate steps were taken to reduce the risk of bias across six domains: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias.

For sequence generation and allocation concealment, we report the methods used. For blinding, we describe who was blinded and the blinding method. For incomplete outcome data, we report the percentage and proportion lost to follow‐up. For selective outcome reporting, we state any discrepancies between the methods used and the results, in terms of the outcomes measured or the outcomes reported. For other biases, we describe any other trial features that we think could affect the trial result (for example, if the trial was stopped early).

We then categorized our judgements as \'low\', \'high\', or \'unclear\' risk of bias, and used this information to guide our interpretation of the presented data. Where our judgement was unclear, we attempted to contact the trial authors for clarification and resolved any differences of opinion through discussion.

### Measures of treatment effect {#CD011547-sec3-0011}

We analysed the data using [@CD011547-bbs2-0030]. Dichotomous data were combined and presented using risk ratios. For continuous data summarized by arithmetic means and standard deviations, we combined data using mean differences. Risk ratios and mean differences are accompanied by 95% CIs.

### Unit of analysis issues {#CD011547-sec3-0012}

We did not encounter any unit of analysis issues.

### Dealing with missing data {#CD011547-sec3-0013}

When trial reports were insufficient, unclear, or missing, we attempted to contact the trial authors for additional information.

### Assessment of heterogeneity {#CD011547-sec3-0014}

We assessed heterogeneity amongst trials by inspecting the forest plots, applying the Chi² test with a 10% level of statistical significance, and also using the I² statistic with a value of 50% used to denote moderate levels of heterogeneity.

### Assessment of reporting biases {#CD011547-sec3-0015}

We planned to assess the possibility of publication bias by examining funnel plots for asymmetry, but there were too few trials to make this meaningful.

### Data synthesis {#CD011547-sec3-0016}

We gave the included trials identity codes which include the three‐letter international country code, and listed the trials in forest plots in chronological order (by the final date of enrolment).

Treatments were compared directly using pair‐wise comparisons. For outcomes that were measured at different time points, we stratified the analysis by the time point.

We performed meta‐analysis where appropriate after assessment and investigation of heterogeneity. In the first instance we used a fixed‐effect model, and used a random‐effects model when the Chi² test P value was less than 0.1 or the I² statistic greater than 50%.

#### Quality of evidence {#CD011547-sec4-0006}

We assessed the quality of evidence for each outcome measure using the GRADE approach. The quality rating across studies has four levels: high, moderate, low, or very low. Randomized trials are initially categorized as high quality but downgraded after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias ([@CD011547-bbs2-0021]).

### Subgroup analysis and investigation of heterogeneity {#CD011547-sec3-0017}

We planned to investigate potential sources of heterogeneity through a series of analyses subgrouping the trials by: geographical region, intensity of malaria transmission (low to moderate versus high malaria transmission), known parasite resistance, allocation concealment, participant age, and drug dose (comparing regimens where there are significant variations in drug dose). However, there were too few trials to make this meaningful.

### Sensitivity analysis {#CD011547-sec3-0018}

We conducted a series of sensitivity analyses to investigate the robustness of the methodology used in the primary analysis. We aimed to restore the integrity of the randomization process by adding excluded groups back into the analysis in a stepwise fashion (see [Table 5](#CD011547-tbl-0005){ref-type="table"} for details).

Results {#CD011547-sec1-0005}
=======

Description of studies {#CD011547-sec2-0007}
----------------------

### Results of the search {#CD011547-sec3-0019}

We identified 15 articles as potentially relevant to this Cochrane Review. Four RCTs met our inclusion criteria and we excluded 11 articles (see [Figure 1](#CD011547-fig-0001){ref-type="fig"}).Figure 1Study flow diagram.

### Included studies {#CD011547-sec3-0020}

The four trials randomized 740 participants with uncomplicated *P. falciparum* malaria. Two trials ([@CD011547-bbs2-0002]; [@CD011547-bbs2-0003]) also included participants with *P. vivax* malaria or mixed infections but we excluded these participants from this review.

The trials were conducted in Benin, Côte d\'Ivoire, Papua New Guinea, and Indonesia. The trial sites in Benin and Côte d\'Ivoire are described as having high transmission intensity and high levels of resistance to chloroquine and SP ([@CD011547-bbs2-0001]; [@CD011547-bbs2-0004]). In Indonesia, there were multiple trial sites which are likely to have covered variable levels of transmission (although this was not explicitly stated), and Indonesia has reported resistance to chloroquine, quinine, and SP ([@CD011547-bbs2-0003]). Endemicity and resistance are not described in the study from Papua New Guinea ([@CD011547-bbs2-0002]).

[@CD011547-bbs2-0001] recruited participants older than six months, [@CD011547-bbs2-0004] recruited children aged six months to 15 years, [@CD011547-bbs2-0002] recruited children aged 6 months to five years, and [@CD011547-bbs2-0003] only recruited adults.

Three trials compared artemisinin‐naphthoquine with a three‐day course of AL, but each trial used a different regimen of artemisinin‐naphthoquine: [@CD011547-bbs2-0001] gave a single dose, [@CD011547-bbs2-0004] gave two doses eight hours apart, and [@CD011547-bbs2-0002] gave a daily dose for three days. It is unclear whether the total dose is comparable across these three trials. [@CD011547-bbs2-0003] compared a single dose of artemisinin‐naphthoquine with a three day course of DHA‐P.

[@CD011547-bbs2-0001] and [@CD011547-bbs2-0004] only report the primary outcome at Day 28 post‐treatment, while [@CD011547-bbs2-0002] and [@CD011547-bbs2-0003] report both Day 28 and Day 42.

### Excluded studies {#CD011547-sec3-0021}

The excluded studies and reasons for their exclusion are given in the \'[Characteristics of excluded studies](#CD011547-sec2-0020){ref-type="sec"}\' table.

Risk of bias in included studies {#CD011547-sec2-0008}
--------------------------------

We summarised the \'Risk of bias\' assessments in [Figure 2](#CD011547-fig-0002){ref-type="fig"} and the reasons for these judgements in the \'[Characteristics of included studies](#CD011547-sec2-0019){ref-type="sec"}\' table.Figure 2Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.

### Allocation {#CD011547-sec3-0022}

Two trials adequately described random sequence generation and allocation concealment to be considered at low risk of selection bias ([@CD011547-bbs2-0002]; [@CD011547-bbs2-0004]). In the other two trials the description was unclear ([@CD011547-bbs2-0001]; [@CD011547-bbs2-0003]).

### Blinding {#CD011547-sec3-0023}

Three trials adequately blinded the outcome assessors (laboratory staff and study physicians) to be at low risk of detection bias. In the remaining trial it was unclear whether outcome assessments had been adequately blinded ([@CD011547-bbs2-0001]).

### Incomplete outcome data {#CD011547-sec3-0024}

All four trials were judged to be of low risk for attrition bias.

### Selective reporting {#CD011547-sec3-0025}

We found no evidence of selective reporting.

### Other potential sources of bias {#CD011547-sec3-0026}

The drug manufacturer was involved in three trials ([@CD011547-bbs2-0001]; [@CD011547-bbs2-0003]; [@CD011547-bbs2-0004]); however, it is clearly stated in one of these that they had no involvement in the design or analysis of the study ([@CD011547-bbs2-0004]).

Effects of interventions {#CD011547-sec2-0009}
------------------------

See: [Table 1](#CD011547-tbl-0001){ref-type="table"}; [Table 2](#CD011547-tbl-0002){ref-type="table"}

### Comparison 1. Artemisinin‐naphthoquine versus AL {#CD011547-sec3-0027}

Three trials compared artemisinin‐naphthoquine with AL. These trials recruited adults and children and administered artemisinin‐naphthoquine as a single dose ([@CD011547-bbs2-0001]), as two doses eight hours apart ([@CD011547-bbs2-0004]), or once daily for three days ([@CD011547-bbs2-0002]). It is unclear whether the total dose is comparable across these three trials.

#### Early clinical response to treatment {#CD011547-sec4-0007}

Two trials reported on fever clearance, with no significant differences between groups in the risk of remaining febrile after 24, 48, or 72 hours (two trials, 321 participants, [Analysis 1.1](#CD011547-fig-00101){ref-type="fig"}).

All three trials reported parasite clearance, with no significant differences between groups at 24, 48 or 72 hours (three trials, 494 participants, [Analysis 1.2)](#CD011547-fig-00102){ref-type="fig"}.

#### Treatment failure {#CD011547-sec4-0008}

Across all three trials, only four participants had recurrent parasitaemia before Day 28, and only two were deemed to have a recrudescence after PCR‐adjustment. Consequently, there were no statistically significant differences between groups (three trials, 487 participants, [Analysis 1.3](#CD011547-fig-00103){ref-type="fig"}; [Analysis 1.4](#CD011547-fig-00104){ref-type="fig"}). The trial from Papua New Guinea continued follow‐up until Day 42, by which time there were five treatment failures with AL (one recrudescence and four new infections) compared to none with artemisinin‐naphthoquine (one trial, 186 participants, [Analysis 1.5](#CD011547-fig-00105){ref-type="fig"}; [Analysis 1.6](#CD011547-fig-00106){ref-type="fig"}).

#### Gametocytemia {#CD011547-sec4-0009}

Two trials reported on gametocyte carriage ([@CD011547-bbs2-0004] and [@CD011547-bbs2-0002]). Gametocyte carriage was very low at baseline in both groups in the trial from Côte d\'Ivoire. Gametocyte carriage was higher at baseline in the trial from Papua New Guinea and AL appeared to clear gametocytes quicker than artemisinin‐naphthoquine (Day 7 gametocyte carriage: RR 2.56, 95% CI 1.42 to 4.60, one trial, 197 participants, [Analysis 1.7](#CD011547-fig-00107){ref-type="fig"}).

#### Anaemia {#CD011547-sec4-0010}

[@CD011547-bbs2-0004] reported the number of participants who were anaemic on Day 7 and found no significant difference between the two groups (one trial, 120 participants, [Analysis 1.8](#CD011547-fig-00108){ref-type="fig"}). [@CD011547-bbs2-0002] presented mean haemoglobin for both groups graphically over 42 days follow‐up. There was a small reduction in mean haemoglobin in both groups during the first week which recovered over the following five weeks. There was no difference between groups at any time point other than Day 42 when mean haemoglobin was slightly lower with AL (P \< 0.001, authors\' own figures).

#### Adverse events {#CD011547-sec4-0011}

Across the three trials only one severe adverse event is described, and this was considered non‐drug‐related; one child given artemisinin‐naphthoquine was admitted and treated for lobar pneumonia ([@CD011547-bbs2-0002]; see [Table 6](#CD011547-tbl-0006){ref-type="table"}).Table 2Serious adverse events**ComparisonTrial IDDescription of severe adverse events provided by publicationART‐NQ versus AL**[@CD011547-bbs2-0001]Not mentioned.[@CD011547-bbs2-0004]\"No severe alterations in renal, haematologic or hepatic function were observed with any of the drug combinations under study.\"\
Other adverse events are described as mild.[@CD011547-bbs2-0002]\"The only severe adverse event was considered non‐drug related. A 48 month old child allocated to artemisinin‐naphthoquine was hospitalized and treated successfully for lobar pneumonia.\"**ART‐NQ versus DHA‐P**[@CD011547-bbs2-0003]\"There were no serious adverse events reported in malaria subjects treated with ART‐NQ and DHA‐P during the study\".

All three trials conducted some form of clinical adverse event monitoring and no differences were reported in clinical symptoms after treatment (three trials, 554 participants, [Analysis 1.9](#CD011547-fig-00109){ref-type="fig"}).

One trial also conducted biochemical monitoring for adverse events on Days 0, 3 and 7. No clinically important differences were seen in tests of renal or liver function ([@CD011547-bbs2-0002]). The same trial also conducted ECG monitoring on Day 0, 2, 3 and 7 in a non‐random sample of participants. After the second dose on day two there were statistically significant differences in the QT interval with 33.3% of those treated with artemisinin‐naphthoquine having a QTc \> 460 msec compared with 3.7% with AL (P value not reported). Differences were not statistically significant at Day 3 or 7.

### Comparison 2. Artemesinin‐naphthoquine versus DHA‐P {#CD011547-sec3-0028}

One multi‐centre trial in Indonesia compared artemisinin‐naphthoquine with DHA‐P ([@CD011547-bbs2-0003]). This trial recruited only adults and administered artemisinin‐naphthoquine as a single dose.

#### Early response to treatment {#CD011547-sec4-0012}

There was no significant differences in fever clearance, or parasite clearance between the two groups (one trial, 149 participants, [Analysis 2.1](#CD011547-fig-00201){ref-type="fig"}; [Analysis 2.2](#CD011547-fig-00202){ref-type="fig"}). All blood slides were clear of parasites by Day 3.

#### Treatment failure {#CD011547-sec4-0013}

There were no PCR‐unadjusted or PCR‐adjusted treatment failures before Day 28 in either group (one trial, 143 participants, [Analysis 2.3](#CD011547-fig-00203){ref-type="fig"}; [Analysis 2.4](#CD011547-fig-00204){ref-type="fig"}). By Day 42, two participants in each group had recurrent parasitaemia, and after PCR‐adjustment the participants given artemisinin‐naphthoquine were deemed to have new infections, and those given DHA‐P were deemed to have recrudescences (one trial, 143 participants; [Analysis 2.5](#CD011547-fig-00205){ref-type="fig"}; [Analysis 2.6](#CD011547-fig-00206){ref-type="fig"}).

#### Gametocytemia {#CD011547-sec4-0014}

On Day 7, there was no significant differences in gametocytaemia between the two trial arms (one trial, 150 participants, [Analysis 2.7](#CD011547-fig-00207){ref-type="fig"}).

#### Anaemia {#CD011547-sec4-0015}

Not reported.

#### Adverse events {#CD011547-sec4-0016}

No serious adverse events were reported, and adverse events were rare with no differences detected between the two treatments (one trial, 152 participants, [Analysis 2.8](#CD011547-fig-00208){ref-type="fig"}; see [Table 6](#CD011547-tbl-0006){ref-type="table"}).

Discussion {#CD011547-sec1-0006}
==========

Summary of main results {#CD011547-sec2-0010}
-----------------------

In three small trials from Benin, Côte d\'Ivoire, and Papua New Guinea, both artemisinin‐naphthoquine and AL had a very low incidence of treatment failure at day 28 (*low quality evidence*).

In a single small study from Indonesia, treatment failure at day 28 and day 42 was very low with both artemisinin‐naphthoquine and DHA‐P (*very low quality evidence*).

These trials were underpowered to detect clinically important differences.

Overall completeness and applicability of evidence {#CD011547-sec2-0011}
--------------------------------------------------

To date, there are only very limited data available on either the efficacy or safety of artemisinin‐naphthoquine and much larger trials, from a wider variety of epidemiological settings will be required before this combination could be recommended. It is perhaps helpful to note that DHA‐P had been evaluated in 22 RCTs enrolling almost 15,000 adults and children before it was formally recommended by the WHO ([@CD011547-bbs2-0031]), and artesunate plus pyronaridine has been evaluated in three large multicentre trials enrolling over 3000 participants but still requires further evidence of efficacy and safety to have confidence in its effects ([@CD011547-bbs2-0017]).

Trials of around 500 participants are required to demonstrate equivalent efficacy in a single setting ([Table 7](#CD011547-tbl-0007){ref-type="table"}), and trials from multiple settings are required to demonstrate that the findings can be generalised to regions or continents, particularly for infectious diseases such as malaria where infection patterns and drug resistance vary widely. To rule out serious side‐effects, particularly rare ones, much larger patient numbers are required and this is usually done through observational cohorts.Table 3Optimal information size calculations**OutcomeHypothesisExamplePowerα errorProportion in control groupProportion in intervention groupMaximum risk differenceTotal sample sizePCR‐adjusted treatment failure**SuperiorityAssuming a 10% failure rate with the old drug and that a new drug should be at least 95% effective80%5%0.100.05---864Non‐inferiorityAssuming that both drugs are 95% effective and that there is no more than a 5% difference in efficacy80%5%0.050.050.05472[^5]

The trials included in this review suggest that this combination has potential, but it is unclear whether the rationale of a shortened 24 hour regimen is justified. The current WHO recommendation for three‐day regimens is based on a trade‐off between compliance (enhanced by shorter regimens), efficacy (enhanced by longer regimens), and the desire to reduce the risk of drug resistance developing (enhanced by combinations of two drugs acting via different mechanisms until parasitaemia is reduced to very low levels). While compliance with the three‐day regimens of established ACTs has been poor in some studies, it is hard to understand why shortening the regimen to 24 hours with artemisinin‐naphthoquine would be any different to ensuring very poor compliance with any other ACT. Consequently, it would probably be preferable if future studies evaluated a three‐day regimen.

Quality of the evidence {#CD011547-sec2-0012}
-----------------------

We assessed the quality of the evidence in this review using the GRADE approach and presented the evidence in two \'Summary of findings\' tables for efficacy ([Table 1](#CD011547-tbl-0001){ref-type="table"}; [Table 2](#CD011547-tbl-0002){ref-type="table"}). We judge the evidence to be of low or very low quality meaning that we have little confidence in the findings of no statistically significant difference between the tested ACTs. We downgraded the evidence by one level for serious indirectness as artemisinin‐naphthoquine has only been evaluated in a limited number of settings and the findings are not easily generalized, and by one or two levels for serious imprecision as the trials are severely underpowered to detect differences.

Potential biases in the review process {#CD011547-sec2-0013}
--------------------------------------

None identified.

Agreements and disagreements with other studies or reviews {#CD011547-sec2-0014}
----------------------------------------------------------

We found two review articles authored by representatives of the pharmaceutical developers ([@CD011547-bbs2-0023]; [@CD011547-bbs2-0015]). Both are narrative overviews rather than systematic reviews. [@CD011547-bbs2-0023] includes the data from the three trials included here plus some additional data from three unpublished trials. We have contacted the pharmaceutical company requesting access to these data but have not yet received it. Should these become available, we will include them in the future updates of this review. [@CD011547-bbs2-0023] concludes that \"ARCO® demonstrated high level of efficaciousness and safety\" but notes that further research is still necessary. We are more conservative in our conclusions, and feel that neither the efficacy nor the safety has yet been reliably established.

Authors\' conclusions {#CD011547-sec1-0007}
=====================

The results of these few trials of artemisinin‐naphthoquine are promising, but further trials from multiple settings are required to reliably demonstrate the relative efficacy and safety compared to established ACTs.Future trials should be adequately powered to demonstrate non‐inferiority, and regimens incorporating three days of the artemisinin component are probably preferable to the one‐day regimens.

We thank Vittoria Lutje for conducting the searches. We also acknowledge the contributions of Sarah Donegan and Piero Olliaro to developing the protocol for [@CD011547-bbs2-0031] which was also used for this Cochrane Review.

This document is an output from a project funded by UKaid from the UK Government for the benefit of developing countries. The views expressed are not necessarily those of the Department for International Development (DFID).

**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS**1malariaMalaria ti, ab, MeshMalaria ti, ab, MeshMalaria ti, ab, Emtreemalaria2arte\*arte\* ti, abarte\* ti, abarte\*Arte\$3dihydroarte\*dihydroarte\* ti, abdihydroarte\* ti, abdihydroarte\*Dihydroarte\$4Coartem\*Coartem\* ti, abCoartem\* ti, abCoartem\$Coartem\$5lumefantrineLumefantrine ti, abLumefantrine ti, ablumefantrinelumefantrine62 or 3 or 4 or 52 or 3 or 4 or 52 or 3 or 4 or 52 or 3 or 4 or 52 or 3 or 4 or 57Naphthoquin\*Naphthoquin\* ti, abNaphthoquin\* ti, abNaphthoquin\* ti, abNaphthoquin\$81 and 6 and 7Naphthoquinones\[Mesh\]Naphthoquinones\[Mesh\]Naphthoquinone \[Emtree\]1 and 6 and 797 or 87 or 87 or 8101 and 6 and 91 and 6 and 91 and 6 and 9

^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([@CD011547-bbs2-0025]).

**Trial IDSample SizeBlindingClinical symptoms monitoringBiochemistryHaematologicalElectrocardiogram**[@CD011547-bbs2-0002]198Open labelStandardized assessment on days 1, 2, 3, 7, 14, 28 and 42.Hepatorenal function on days 0, 3 and 7.Full blood count, on days 0, 3 and 7.Electrocardiogram on days 0, 3 and 7. An additional electrocardiogram was performed 4 hours after day 2 dose in those treated with ART‐NQ and in a convenience sample of 30 people treated with artemether‐lumefantrine.[@CD011547-bbs2-0003]243Open labelLimited physical exam on days 1 to 2, 3, 7, 14, 12, 28, 35, and 42 and if clinically indicated.Blood chemistry at days 3, 7, and 28.Haematology at days 3, 7, and 28.ECG 2 to 4 hours after drug administration and on follow‐up days 7, 28, and 42.[@CD011547-bbs2-0001]174SinglePatients were hospitalized for the first three days, and monitored clinically; following discharge patients were seen on days 7, 14, 21, 28 and a symptom questionnaire was conducted at each visit.Biochemistry (U and E, LFT) whilst patients were hospitalized for the first three days; then following discharge on days 7, 14, 21, 28.Haematology whilst patients were hospitalized for the first three days; then following discharge on days 7, 14, 21, 28.---[@CD011547-bbs2-0004]125SingleFollow‐up: on days 1, 2, 3, 7, 14, 21, and 28 (or any other day if they felt ill). Follow‐up evaluation was history and examination. \"All observed adverse events were monitored actively and passively from the time the participant has taken one dose of study treatment through last visit, and were recorded on the Case Report Form (CRF) according to Good Clinical Practice (GCP) and ICH guidelines.\"Day 7 follow‐up included liver profile.Day 7 follow‐up included liver profile.---

Comparison 1Artemisinin‐naphthoquine versus ALOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Fever clearance](#CD011547-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 1 Fever clearance.2Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only1.1 Fever on day 12321Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.48, 1.29\]1.2 Fever on day 22319Risk Ratio (M‐H, Fixed, 95% CI)2.73 \[0.89, 8.43\]1.3 Fever on day 32320Risk Ratio (M‐H, Fixed, 95% CI)1.17 \[0.39, 3.52\][2 Parasite clearance](#CD011547-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 2 Parasite clearance.3Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only2.1 Parasitaemia on day 13494Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.86, 1.19\]2.2 Parasitaemia on day 23494Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.43, 1.80\]2.3 Parasitaemia on day 33494Risk Ratio (M‐H, Fixed, 95% CI)2.0 \[0.18, 21.70\][3 PCR‐unadjusted treatment failure at day 28](#CD011547-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 3 PCR‐unadjusted treatment failure at day 28.3487Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.24, 4.37\][4 PCR‐adjusted treatment failure at day 28](#CD011547-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 4 PCR‐adjusted treatment failure at day 28.3485Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.15, 7.07\][5 PCR‐unadjusted treatment failure at day 42](#CD011547-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 5 PCR‐unadjusted treatment failure at day 42.1186Risk Ratio (M‐H, Fixed, 95% CI)0.09 \[0.00, 1.59\][6 PCR‐adjusted treatment failure at day 42](#CD011547-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 6 PCR‐adjusted treatment failure at day 42.1186Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 7.91\][7 Gametocyte carriage](#CD011547-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 7 Gametocyte carriage.2Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only7.1 At baseline2321Risk Ratio (M‐H, Fixed, 95% CI)1.25 \[0.87, 1.80\]7.2 At day 72320Risk Ratio (M‐H, Fixed, 95% CI)2.56 \[1.42, 4.60\]7.3 At day 141197Risk Ratio (M‐H, Fixed, 95% CI)13.13 \[1.75, 98.47\][8 Anaemia](#CD011547-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 8 Anaemia.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected8.1 At baseline1Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.2 On day 71Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][9 Adverse events](#CD011547-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Artemisinin‐naphthoquine versus AL, Outcome 9 Adverse events.3Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only9.1 Vomiting2380Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.39, 2.64\]9.2 Diarrhoea2380Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.30, 2.54\]9.3 Nausea2297Risk Ratio (M‐H, Fixed, 95% CI)0.95 \[0.40, 2.25\]9.4 Abdominal pain3554Risk Ratio (M‐H, Fixed, 95% CI)1.34 \[0.73, 2.45\]9.5 Anorexia1123Risk Ratio (M‐H, Fixed, 95% CI)2.95 \[0.32, 27.60\]9.6 Dizziness1123Risk Ratio (M‐H, Fixed, 95% CI)1.97 \[0.18, 21.14\]9.7 Headaches1257Risk Ratio (M‐H, Fixed, 95% CI)1.33 \[0.61, 2.92\]9.8 Asthenia1123Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.06, 15.38\]9.9 Trouble sleeping1257Risk Ratio (M‐H, Fixed, 95% CI)2.05 \[0.19, 22.30\]9.10 Cough1257Risk Ratio (M‐H, Fixed, 95% CI)1.22 \[0.81, 1.84\]9.11 Difficulty breathing1257Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.06, 16.19\]9.12 Pruritus2297Risk Ratio (M‐H, Fixed, 95% CI)1.46 \[0.29, 7.34\]9.13 Skin rash1257Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.26, 4.00\]

Comparison 2Artemisinin‐naphthoquine versus DHA‐POutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Fever clearance](#CD011547-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 1 Fever clearance.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected1.1 Fever on day 21Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]1.2 Fever on day 31Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][2 Parasite clearance](#CD011547-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 2 Parasite clearance.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected2.1 Parasitaemia on day 11Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]2.2 Parasitaemia on day 21Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]2.3 Parasitaemia on day 31Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][3 PCR‐unadjusted treatment failure at day 28](#CD011547-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 3 PCR‐unadjusted treatment failure at day 28.1143Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][4 PCR‐adjusted treatment failure at day 28](#CD011547-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 4 PCR‐adjusted treatment failure at day 28.1143Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][5 PCR‐unadjusted treatment failure at day 42](#CD011547-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 5 PCR‐unadjusted treatment failure at day 42.1143Risk Ratio (M‐H, Fixed, 95% CI)0.91 \[0.13, 6.26\][6 PCR‐adjusted treatment failure at day 42](#CD011547-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 6 PCR‐adjusted treatment failure at day 42.1141Risk Ratio (M‐H, Fixed, 95% CI)0.19 \[0.01, 3.82\][7 Gametocyte carriage](#CD011547-fig-00207){ref-type="fig"}Analysis 2.7Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 7 Gametocyte carriage.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected7.1 At baseline1Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]7.2 At day 71Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][8 Adverse events](#CD011547-fig-00208){ref-type="fig"}Analysis 2.8Comparison 2 Artemisinin‐naphthoquine versus DHA‐P, Outcome 8 Adverse events.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only8.1 Vomiting1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.2 Diarrhoea1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.3 Nausea1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.4 Anorexia1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.5 Dizziness1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.6 Asthenia1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.7 Abdominal pain1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.8 Pruritus1152Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8.9 Cough1152Risk Ratio (M‐H, Fixed, 95% CI)1.85 \[0.17, 19.95\]

Characteristics of included studies \[ordered by study ID\] {#CD011547-sec2-0019}
===========================================================

[@CD011547-bbs2-0001]MethodsTrial design: RCT\
Follow‐up: Patients were hospitalized for the first three days, and monitored clinically and biochemically. Following discharge patients were seen on Day 7, 14, 21, and 28 with a malaria blood film at each visit.\
Adverse event monitoring: A symptom questionnaire, biochemistry (U and E, LFT), and haematology were conducted at each visit.ParticipantsNumber: 174 participants randomized\
Inclusion criteria: Age 6 months to 15 years, clinical signs of uncomplicated malaria, temp \> 37.5°C or history of fever in the last 24 hours, asexual *P. falciparum* density \> 2000/μL, able to take oral medication, informed consent.\
Exclusion criteria: Signs of severe malaria, known hypersensitivity to study medications, treatment with antimalarials within the past 7 days, positive pregnancy test.\
In addition the trial authors state that they planned to exclude the following groups from the study: severe toxicity, abnormal biochemical tests, unsatisfactory therapeutic response. However, no participants appear to have been excluded for these reasons.Interventions1. Artemesinin‐naphthoquine 125 mg/50 mg, fixed‐dose combination (Arco, Kunming Pharmaceutical Corporation, China):\
weight \< 10 kg 1 tablet, single doseweight 10 to 15 kg 2 tablets, single doseweight 16 to 25 kg 4 tablets, single doseweight 26 to 35 kg 6 tablets, single doseweight \> 35 kg 8 tablets, single dose\
2. AL 20 mg/120 mg, fixed‐dose combination (Coartem, Novartis SA, Switzerland):\
weight \< 15 kg 1 tablet, twice a day for 3 daysweight 15 to 24 kg 2 tablets, twice a day for 3 daysweight 25 to 35 kg 3 tablets, twice a day for 3 daysweight \> 35 kg 4 tablets, twice a day for 3 daysOutcomesPCR‐adjusted and PCR‐unadjusted treatment failure at Day 28HaemoglobinAdverse eventFever clearanceParasite clearanceNotesCountry: Benin\
Setting: Hospital\
Transmission: High\
Resistance: Chloroquine and SP\
Dates: July to Oct 2008 and May to Sept 2009\
Funding: None stated, however the randomization procedure was done by the manufacturer of artemisinin‐naphthoquine***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"According to a randomization method\".Allocation concealment (selection bias)Unclear riskNone described.Blinding of participants and personnel (performance bias) All outcomesHigh riskDescribed as \"single blind\", however as the drug regimens differed significantly blinding of patients and personnel is unlikely.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNo blinding described.Incomplete outcome data (attrition bias) All outcomesLow riskNo loss to follow‐up reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasUnclear riskFunding is unclear, but the pharmaceutical company appear to be involved.[@CD011547-bbs2-0002]MethodsTrial design: open‐label, randomized controlled trial\
Follow‐up: Standardized assessment including axillary temp and blood film on Days 1, 2, 3, 7, 14, 28 and 42.\
Adverse event monitoring: Standardized assessment at each visit plus blood tests for full blood count, hepatorenal function, and an electrocardiogram on Days 0, 3 and 7. An additional electrocardiogram was performed 4 hours after Day 2 dose in those treated with ART‐NQ and in a convenience sample of 30 people treated with artemether‐lumefantrine.ParticipantsNumber: 198 participants with *P. falciparum* randomized.\
Inclusion criteria: Age 6 months to 5 years, axillary temp \> 37.5°C or history of fever in the last 24 hours, asexual *P. falciparum* density \> 1000/μL, or *P. vivax* \> 250/μL.\
Exclusion criteria: Signs of severe malaria, taken study drug in the previous 14 days, known allergy to study medications, evidence of other infection or co‐morbidity.Interventions1. Artemesinin‐naphthoquine; fixed‐dose combination (Kunming Pharmaceutical Corporation, China):\
Artemisinin 20 mg/kg plus naphthoquine 8 mg/kg daily for 3 daysDosed as 1 to 4 whole tablets per dose as per manufacturers instructions\
2. AL: fixed‐dose combination (Novartis Pharma, Switzerland):\
Artemether 1.7 mg/kg plus lumefantrine 10 mg/kg, twice daily for three daysDosed as 1 to 3 whole tablets per dose (plus 250 mL of milk) as per manufacturer\'s instructions.\
Direct observation of morning AL dose onlyOutcomesPCR‐adjusted and PCR‐unadjusted treatment failure at day 28 and day 42Fever clearanceParasite clearanceGametocyte carriageHaematological and biochemical adverse eventsClinical adverse eventsNotesCountry: Papua New Guinea\
Setting: Health centres\
Transmission: Not described\
Resistance: Not described\
Dates: March 2011 to April 2013\
Funding: National Health and Medical Research Council, Australian Award PhD Scholarship, Esso‐Highlands PNGIMR scholarship***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Computer‐generated block randomization\".Allocation concealment (selection bias)Low risk\"Allocated treatments were concealed in sealed numbered envelopes that were opened in sequence by study medical or nursing staff, and the specified treatment was administered.\"Blinding of participants and personnel (performance bias) All outcomesHigh risk\"Treatments were not blinded, primarily because the endpoints were based on objective clinical and parasitologic criteria\".Blinding of outcome assessment (detection bias) All outcomesLow risk\"All blood films were reexamined independently by two skilled microscopists who were blind to allocated treatment.\"Incomplete outcome data (attrition bias) All outcomesLow riskAt day 28: 2/98 (2%) were lost to follow‐up with artemisinin‐naphthoquine versus 6/100 (6%) with artemether‐lumefantrine.\
At day 42: 4/98 (4%) were lost to follow‐up with artemisinin‐naphthoquine versus 8/100 (8%) with artemether‐lumefantrine.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow risk\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"[@CD011547-bbs2-0003]MethodsTrial design: A phase III, randomized, open label, multi‐centre, comparative study.\
Follow‐up: Limited physical exam on Days 1‐2, 3, 7, 14, 12, 28, 35, and 42 and if clinically indicated. ECG 2 to 4 hours after drug administration and on follow‐up Days 7, 28, and 42. Thick and thin smears eight hourly in Days 0 to 2, then Days 3, 7, 14, 21, 28, 35, and 42. Haematology and blood chemistry at Days 3, 7, and 28. Blood spot for PCR at Day 42 or failure. Urinalysis on Day 3. HCG for women on Days 0 and 28.\
Adverse event monitoring: \"adverse events collected each time\" and \"Safety was assessed through direct questioning, physical examinations, ECG abnormalities (prolongation QT‐interval), and significant change from baseline clinical laboratory parameters \[17\]. Adverse events were followed up until the event had resolved.\"ParticipantsNumber: 401 randomized (153 *P. falciparum* only, 90 mixed, 158 *P. vivax* only).\
Inclusion criteria: adult, absence of severe malnutrition, axillary temperature \> 37.5°C or a history of fever within the preceding 24 hours, asexual *P. falciparum* density 1000 to 200,000/μL, *P. vivax* and other malaria density ≥ 250/μL, able to take oral treatment, informed consent, uncomplicated *P. falciparum* or *P. vivax* mono‐infection, or mixed infection.\
Exclusion criteria: severe vomiting, history or evidence of \'clinically systematic significant disorders\', other febrile conditions, hypersensitivity or adverse reactions to antimalarials, history of use of any other antimalarial agent within four weeks of the start of the trial and confirmed by urine test, and pregnancy or lactating.Interventions1. Artemesinin‐naphthoquine, fixed‐dose combination, 250 mg/100 mg tablets (Arco, Kunming Pharmaceutical Corporation, China):\
4 tablets as a single dose\
2. DHA‐P, fixed‐dose combination, 40 mg/320 mg tablets (Duo‐Cotecxin: Holey‐Cotec Pharmaceutical Co. Ltd, China):\
Daily doses of dihydroartemisinin 2 to 4 mg/kg and piperaquine 16 to 32 mg/kgweight ≤ 60 kg 3 tablets each day for 3 daysweight \> 60 kg 4 tablets each day for 3 days\
All doses supervised.OutcomesACPR at Day 42, PCR‐adjusted and PCR‐unadjustedGametocyte carriageAdverse eventsFever clearanceParasite clearanceNotesCountry: Indonesia\
Setting: Three Armed Forces hospitals in Jayapura (Marthen Indeys/Army, Soedibjo Sardadi/Navy, and Bhayangkara/Police Hospitals) and one public hospital in Maumere (St. Gabriel Hospital)\
Transmission: Not reported\
Resistance: Widely reported resistance of *P. falciparum* to chloroquine, sulphadoxine‐pyrimethamine, and quinine\
Dates: 2007 to 2008\
Funding: Kunming Pharmaceutical Corporation***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Eligible subjects were blindly, randomly assigned equally to one of the two treatment groups using sealed envelopes\".Allocation concealment (selection bias)Low risk\"Eligible subjects were blindly, randomly assigned equally to one of the two treatment groups using sealed envelopes\".Blinding of participants and personnel (performance bias) All outcomesHigh riskTrial described as \"open label\".Blinding of outcome assessment (detection bias) All outcomesLow risk\"Microscopy results were blind cross‐checked by certified microscopists\".Incomplete outcome data (attrition bias) All outcomesLow riskLow losses to follow‐up in both groups (3.5% AS‐N versus 5% DHA‐P).Selective reporting (reporting bias)Low riskAll listed outcomes reported.Other biasUnclear risk\"We also thank to Kunming Pharmaceutical Corporation for funding the artemisinin‐naphthoquine trial.\"\
The role of the pharmaceutical company in the design, conduct, and interpretation of the trial is unclear.[@CD011547-bbs2-0004]MethodsTrial design: randomized single‐blinded clinical trial\
Follow‐up: on Days 1, 2, 3, 7, 14, 21, and 28 (or any other day if they felt ill). Follow‐up evaluation was history and examination. Day 7 follow‐up included full blood count and liver profile. Blood spots collected for PCR on day of failure.\
Adverse event monitoring: \"All observed adverse events were monitored actively and passively from the time the participant has taken one dose of study treatment through last visit, and were recorded on the Case Report Form (CRF) according to Good Clinical Practice (GCP) and ICH guidelines.\"ParticipantsNumber: 125 randomized\
Inclusion criteria: ≥ six months old, *P. falciparum* monoinfection with parasitaemia level of 2000 to 200,000 asexual parasites/μL, axillary temperature \> 37.5°C or a history of fever within the preceding 24 hours, no history of serious side effects to study medications, no evidence of concomitant febrile illness, provision of written informed consent by the participant or parent/guardian.\
Exclusion criteria: symptoms or signs of severe malaria, or both, any \"danger sign\" (persistent vomiting; inability to sit, stand, drink or breast feed), recent history of convulsions or lethargy, or both, or otherwise impaired consciousness, haemoglobin concentration ≤ 6 mg/dL, serious underlying disease, or known allergy to the study drugs.\
\"Participants were also excluded after randomization, if they repeatedly vomited their first dose of study medications.\"\
\"Participants were excluded after enrolment if any of the following occurred: (1) use of antimalarial drugs outside of the study protocol; (2) parasitaemia in the presence of a concomitant febrile illness; (3) withdrawal of consent; (4) loss to follow‐up, (5) protocol violation, or (6) death due to a non‐malaria illness.\"Interventions1. Artemesinin‐naphthoquine, 125 mg/50 mg fixed‐dose combination at 0, 8 hours (Arco, Kunming Pharmaceutical Corporation, China):\
weight 6 to 10 kg ½ crushed tablet, 2 dosesweight 10 to 15 kg 1 crushed tablet, 2 dosesweight 15 to 25 kg 2 crushed tablets, 2 dosesweight 25 to 35 kg 3 tablets, 2 dosesweight ≥ 35 kg 4 tablets, 2 doses\
2. AL fixed‐dose combination (Coartem, Novartis SA, Switzerland):\
weight 5 to 15 kg 1 crushed tablet, twice a day for 3 daysweight 15 to 25 kg 2 crushed tablets, twice a day for 3 daysweight 25 to 35 kg 3 tablets, twice a day for 3 daysweight ≥ 35 kg 4 tablets, twice a day for 3 days\
Morning doses supervised and evening doses taken at home. \"The empty sachets were returned to study site as evidence of taking the drug\".OutcomesPCR‐adjusted and PCR‐unadjusted treatment failure at day 28Gametocyte carriageAdverse eventsFever clearanceParasite clearanceNotesCountry: Côte d\'Ivoire\
Setting: Primary care centre in Anonkoua‐kouté (crowded sub‐urban area)\
Transmission: \"extremely high transmission intensity\" and \"holoendemic\".\
Resistance: \"*Plasmodium falciparum* resistance to affordable anti‐malarial drugs (chloroquine and sulphadoxine‐pyrimethamine) has reached high levels\".\
Dates: November 2006 to January 2007\
Funding: Institut Pasteur, Kunming Pharmaecutical Corporation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Participants recruited into the study were allocated to two treatment groups using a computer generated random list based on a simple random selection procedure without the use of blocking or stratification by an off‐site investigator.\"Allocation concealment (selection bias)Low risk\"Sequentially numbered, sealed envelopes containing the treatment group assignments were prepared from the randomization list. The study clinical investigators assigned treatment numbers sequentially and a third party investigator who is an appropriately qualified member of the study site, allocated treatment by opening the envelope corresponding to the treatment number. The randomization codes were secured in a locked cabinet accessible only by the third party. Participants were enrolled by the study physicians, and treatments were assigned and administered by the third party.\"Blinding of participants and personnel (performance bias) All outcomesLow risk\"Participants were not informed of their treatment regimen.\"\
Comment: As the regimens are different and no placebos were used participants were essentially unblinded to treatment.Blinding of outcome assessment (detection bias) All outcomesLow risk\"Only the third party was aware of treatment assignments. All other study personnel, including the study physicians and laboratory personnel involved in assessing outcomes, were blinded to the treatment assignments.\"Incomplete outcome data (attrition bias) All outcomesLow riskOne participant from each group didn\'t complete the study: 1 from AN lost to follow‐up and 1 from AL excluded.Selective reporting (reporting bias)Low riskAll listed outcomes reported.Other biasLow riskNo other sources of bias identified.\
\"Artemisinin/naphthoquine and Artemether/lumefantrine were provided free of charge respectively by Kunming Pharmaceutical Corp. and Novartis S A. The funders had no involvement in the study design, data collection and its analysis and interpretation, in the writing of paper or in decision to submit it for publication\".

Characteristics of excluded studies \[ordered by study ID\] {#CD011547-sec2-0020}
===========================================================

StudyReason for exclusion[@CD011547-bbs2-0005]Study 1 ‐ no control group. Study 2 ‐ not a relevant comparison. This study is a pharmacokinetic study comparing a single dose of AS‐N with two doses of AS‐N given 24 hours apart.[@CD011547-bbs2-0006]Not a relevant comparison: this study compares a single dose of AS‐N given with water versus a single dose of AS‐N given with milk versus two doses of AS‐N.[@CD011547-bbs2-0007]Not a relevant comparison: this study compares naphthoquine monotherapy with artesunate monotherapy or mefloquine monotherapy.[@CD011547-bbs2-0008]Not a relevant comparison: this study compares a single dose of ART‐NQ with a three day course of chloroquine plus sulphadoxine‐pyrimethamine.[@CD011547-bbs2-0009]A review article: discusses a pharmacokinetic study ([@CD011547-bbs2-0005]).[@CD011547-bbs2-0010]Not a relevant comparison: this study compares a three day course of ART‐NQ with CQ plus primaquine for treating *P. vivax*.[@CD011547-bbs2-0011]Not a relevant comparison: this study compares a single dose of ART‐NQ versus a high single dose of ART‐NQ versus two dose of ART‐NQ.[@CD011547-bbs2-0012]No control group: a single arm trial of a single dose ART‐NQ in adults with uncomplicated *P. falciparum* malaria.[@CD011547-bbs2-0013]No control group: single‐arm trial of dihydroartemisinin combined with naphthoquine.[@CD011547-bbs2-0014]Not randomized.[@CD011547-bbs2-0015]A review article.

DS and BZ contributed to the development of the standard protocol as used in [@CD011547-bbs2-0031]. BZ drafted the background. RI and MG reviewed the reference list, extracted data, and entered it into [@CD011547-bbs2-0030]. RI, MG, and DS conducted the analyses, constructed \'Summary of findings\' tables, and evaluated the quality of evidence using the GRADE approach. RI wrote the first draft and all authors reviewed and contributed to the final draft.

Internal sources {#CD011547-sec2-0017}
================

Liverpool School of Tropical Medicine, UK.

External sources {#CD011547-sec2-0018}
================

Department for International Development (DFID), UK.

The review authors have no conflicting interests.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^ No serious risk of bias: Two studies adequately concealed allocation to be at low risk of selection bias. In the other study the process of randomization and allocation concealment was unclear. ^2^ No serious inconsistency: Statistical heterogeneity was low. ^3^ Downgraded by 1 for serious indirectness: Three studies have now evaluated this comparison, but only one used a three‐day regimen as recommended by the WHO. The three studies are from Benin, Côte d\'Ivoire, and Papua New Guinea, and the level of treatment failure with both artemisinin‐naphthoquine and AL was very low, lower than seen in many trials of AL. Further studies from additional settings are required before this result can be generalized to elsewhere. ^4^ Downgraded by 1 for serious imprecision: to demonstrate non‐inferiority at 95% efficacy requires a sample size of 472. These trials are individually significantly underpowered, and the number of events is too low to have full confidence in this result. ^5^ No serious risk of bias: This study adequately concealed allocation to be at low risk of selection bias. ^6^ Downgraded by 1 for serious indirectness: This single study is from Papua New Guinea. Further studies from additional settings are required before this result can be generalized to elsewhere. ^7^ Downgraded by 2 for very serious imprecision: This trial is significantly underpowered to demonstrate non‐inferiority.

[^3]: ^1^ No serious risk of bias: Although the description of the randomization procedure is vague, this trial is probably at low risk of selection bias. ^2^ Downgraded by 1 for serious indirectness: This comparison has only been evaluated in a single setting. Further studies from additional settings are required before this result can be generalized to elsewhere. ^3^ Downgraded by 2 for very serious imprecision: to demonstrate non‐inferiority at 95% efficacy would require a sample size of 472. This trial is significantly underpowered.

[^4]: ^a^ Note: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations. ^b^ PCR: polymerase chain reaction. ^c^ \'Excluded\' means removed from the calculation. ^d^ To re‐classify all indeterminate or missing PCR results as treatment failures in the PCR‐adjusted analysis. ^e^ To re‐classify all PCR‐confirmed new infections as treatment successes in the PCR‐adjusted analysis. (This analysis may overestimate efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may have gone on to develop a recrudescence after the new infection.) ^f^ To re‐classify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment failures. For PCR‐unadjusted total failure this represents a true worse‐case scenario. ^g^ To re‐classify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment successes.

[^5]: We performed calculations with http://www.sealedenvelope.com
